MA35185B1 - Nouveaux composés en tant qu'inhibiteurs de diacylglycérol acyltransférase - Google Patents

Nouveaux composés en tant qu'inhibiteurs de diacylglycérol acyltransférase

Info

Publication number
MA35185B1
MA35185B1 MA36566A MA36566A MA35185B1 MA 35185 B1 MA35185 B1 MA 35185B1 MA 36566 A MA36566 A MA 36566A MA 36566 A MA36566 A MA 36566A MA 35185 B1 MA35185 B1 MA 35185B1
Authority
MA
Morocco
Prior art keywords
dgat
inhibitors
diacylglycerol acyltransferase
obesity
new compounds
Prior art date
Application number
MA36566A
Other languages
English (en)
French (fr)
Inventor
Donghui Qin
Mui Cheung
Hemant Joshi
Raghuram Tangirala
Sridhar Reddy Bethi
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of MA35185B1 publication Critical patent/MA35185B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA36566A 2011-05-20 2013-12-13 Nouveaux composés en tant qu'inhibiteurs de diacylglycérol acyltransférase MA35185B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1452DE2011 2011-05-20
US201161503728P 2011-07-01 2011-07-01
PCT/US2012/038523 WO2012162129A1 (en) 2011-05-20 2012-05-18 Novel compounds as diacylglycerol acyltransferase inhibitors

Publications (1)

Publication Number Publication Date
MA35185B1 true MA35185B1 (fr) 2014-06-02

Family

ID=47217645

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36566A MA35185B1 (fr) 2011-05-20 2013-12-13 Nouveaux composés en tant qu'inhibiteurs de diacylglycérol acyltransférase

Country Status (34)

Country Link
US (4) US8859536B2 (enExample)
EP (1) EP2710013B1 (enExample)
JP (1) JP5844456B2 (enExample)
KR (1) KR101919080B1 (enExample)
CN (1) CN103703009B (enExample)
AU (1) AU2012259044B2 (enExample)
BR (1) BR112013029935B1 (enExample)
CA (1) CA2836669C (enExample)
CO (1) CO6811855A2 (enExample)
CR (1) CR20130602A (enExample)
CY (1) CY1118188T1 (enExample)
DK (1) DK2710013T3 (enExample)
DO (1) DOP2013000272A (enExample)
EA (1) EA023030B1 (enExample)
ES (1) ES2588748T3 (enExample)
HR (1) HRP20161089T1 (enExample)
HU (1) HUE028870T2 (enExample)
IL (1) IL229488A (enExample)
LT (1) LT2710013T (enExample)
MA (1) MA35185B1 (enExample)
ME (1) ME02479B (enExample)
MX (1) MX346494B (enExample)
MY (1) MY184553A (enExample)
PE (1) PE20141204A1 (enExample)
PH (1) PH12013502401A1 (enExample)
PL (1) PL2710013T3 (enExample)
PT (1) PT2710013T (enExample)
RS (1) RS55006B1 (enExample)
SG (1) SG195044A1 (enExample)
SI (1) SI2710013T1 (enExample)
SM (1) SMT201600328B (enExample)
UA (1) UA111360C2 (enExample)
WO (1) WO2012162129A1 (enExample)
ZA (1) ZA201308664B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101919080B1 (ko) 2011-05-20 2018-11-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물
EP3492474B1 (en) 2012-11-23 2021-08-11 GlaxoSmithKline LLC Intermediates used in the production of diacylglycerol acyltransferase inhibitors
WO2014081996A1 (en) * 2012-11-23 2014-05-30 Glaxosmithkline Llc Novel compounds as diacylglycerol acyltransferase inhibitors
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
CN103524431B (zh) * 2013-09-24 2016-01-13 西安交通大学 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用
WO2015049668A1 (en) 2013-10-03 2015-04-09 Glaxosmithkline Intellectual Property (No.2) Limited Novel compound as a diacylglycerol acyltransferase inhibitor
WO2015049667A1 (en) 2013-10-03 2015-04-09 Glaxosmithkline Intellectual Property (No.2) Limited Novel compound as a diacylglycerol acyltransferase inhibitor
CN103880757B (zh) * 2014-04-15 2016-02-24 上海毕得医药科技有限公司 一种5-羟基嘧啶-2-羧酸的合成方法
WO2016181409A1 (en) 2015-05-11 2016-11-17 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome -
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
CN105732461A (zh) * 2016-02-03 2016-07-06 常州工程职业技术学院 5-甲氧基-6-卤代吲哚的制备方法
CN106083707B (zh) * 2016-06-01 2018-10-26 温州大学 一种非对称杂芳基硫醚的合成方法
CN107619932B (zh) * 2016-07-15 2020-08-07 中国科学院上海有机化学研究所 一种萃取组合物、萃取体系及其应用
CN107619928B (zh) * 2016-07-15 2020-08-07 中国科学院上海有机化学研究所 一种萃取组合物、萃取体系及其应用
RU2706655C1 (ru) * 2019-01-28 2019-11-19 Акционерное общество "Гознак" (АО "Гознак") Полимерсодержащее композиционное защищенное изделие
CN117603242B (zh) * 2023-11-30 2026-08-11 沧州普瑞东方科技有限公司 一种反式-1-乙氧乙烯基-2-硼酸频那醇酯的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090036425A1 (en) * 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
KR101685718B1 (ko) * 2008-12-19 2016-12-12 제넨테크, 인크. 헤테로시클릭 화합물 및 사용 방법
TW201038580A (en) * 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
JP2012520887A (ja) * 2009-03-18 2012-09-10 シェーリング コーポレイション ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物
ES2513915T3 (es) 2009-04-24 2014-10-27 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
KR101919080B1 (ko) 2011-05-20 2018-11-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors

Also Published As

Publication number Publication date
CN103703009A (zh) 2014-04-02
AU2012259044B2 (en) 2015-09-17
US20160200736A1 (en) 2016-07-14
US9540400B2 (en) 2017-01-10
AU2012259044A1 (en) 2013-12-12
SG195044A1 (en) 2013-12-30
PT2710013T (pt) 2016-09-28
SI2710013T1 (sl) 2016-10-28
MX2013013566A (es) 2014-01-08
CO6811855A2 (es) 2013-12-16
DOP2013000272A (es) 2014-05-15
KR20140045415A (ko) 2014-04-16
IL229488A (en) 2016-04-21
UA111360C2 (uk) 2016-04-25
HUE028870T2 (en) 2017-01-30
US8859536B2 (en) 2014-10-14
BR112013029935A2 (pt) 2016-09-20
HRP20161089T1 (hr) 2016-10-21
NZ617991A (en) 2015-06-26
US9040517B2 (en) 2015-05-26
ES2588748T3 (es) 2016-11-04
CA2836669A1 (en) 2012-11-29
CA2836669C (en) 2019-03-19
HK1194738A1 (zh) 2014-10-24
IL229488A0 (en) 2014-01-30
ME02479B (me) 2017-02-20
EP2710013B1 (en) 2016-06-29
US9273069B2 (en) 2016-03-01
JP2014517839A (ja) 2014-07-24
SMT201600328B (it) 2016-11-10
EP2710013A1 (en) 2014-03-26
WO2012162129A1 (en) 2012-11-29
EA201391737A1 (ru) 2014-04-30
RS55006B1 (sr) 2016-11-30
KR101919080B1 (ko) 2018-11-16
LT2710013T (lt) 2016-09-12
PE20141204A1 (es) 2014-10-05
PH12013502401A1 (en) 2015-10-07
MX346494B (es) 2017-03-21
JP5844456B2 (ja) 2016-01-20
ZA201308664B (en) 2015-02-25
MY184553A (en) 2021-04-02
BR112013029935B1 (pt) 2020-12-15
CN103703009B (zh) 2016-08-17
DK2710013T3 (en) 2016-09-26
EA023030B1 (ru) 2016-04-29
PL2710013T3 (pl) 2017-08-31
EP2710013A4 (en) 2014-11-05
CY1118188T1 (el) 2017-06-28
US20150225425A1 (en) 2015-08-13
CR20130602A (es) 2014-08-13
US20140080809A1 (en) 2014-03-20
US20140378434A1 (en) 2014-12-25

Similar Documents

Publication Publication Date Title
EA201391737A1 (ru) Новые соединения в качестве ингибиторов диацилглицеролацилтрансферазы
EA032971B1 (ru) Соль берберина и урсодезоксихолевой кислоты и ее применение
BR112014016165A8 (pt) compostos de benzaldeído substituído e métodos para seu uso no aumento da oxigenação do tecido
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
EA201300558A1 (ru) Соединения и способы для купирования боли
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201390826A1 (ru) ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201291034A1 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ B-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
EA201391670A1 (ru) 1,3-оксазины в качестве ингибиторов bace1 и/или bace2
EP2855435A4 (en) DENDRIMOUS AMINOAMIDE WITH SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF XEROPHTHALMIA AND OTHER MEASURED TIPS
EA201690521A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
MX2013008213A (es) N-[3-(5-amino-3,3a,7,7a-tetrahidro-1h-2,4-dioxa-6-aza-inden-7-il) -fenil]-amidas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201291092A1 (ru) Гетероарилциклогексил-тетраазабензо[е]азулены в качестве антагонистов рецептора вазопрессина v1a
MA20150429A1 (fr) Benzamides
UA109414C2 (uk) Арильовані камфени та фармацевтична композиція на їх основі
BR112014006763A2 (pt) n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1
EA201491081A1 (ru) Композиции и способы для лечения заболеваний и расстройств печени
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
EP2563794A4 (en) INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY AND ITS USE FOR THE TREATMENT OF EYE DISEASES
WO2012142615A3 (en) Auranofin and auranofin analogs useful to treat proliferative disease and disorders
MX382630B (es) Compuestos de pirazol disustituidos para el tratamiento de enfermedades.
EA201790315A1 (ru) Модуляторы x-рецепторов печени
FR2981936B1 (fr) Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.